...
首页> 外文期刊>Head and neck: Journal for the sciences and specialities of the head and neck >Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
【24h】

Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma.

机译:在局部晚期鼻咽癌的新辅助化疗后采用强度增强的放射疗法和同时的综合增强技术。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Our aim was to evaluate the feasibility and efficacy of intensity-modulated radiation therapy (IMRT) with simultaneous integrated boost (SIB) technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal cancer (NPC). METHODS: Between April 2004 and December 2006, 25 patients with stage IIB to IVB NPC underwent 3 cycles of neoadjuvant chemotherapy followed by IMRT using SIB technique. Neoadjuvant chemotherapeutic regimens were 5-fluorouracil and cisplatin in 11 patients; docetaxel, 5-fluorouracil, and cisplatin in 8; and paclitaxel and cisplatin in 6. Dose prescription of IMRT was as follows: 67.5 Gy at 2.25 Gy/fraction to postchemotherapy gross tumor, 54 to 60 Gy at 1.8 to 2 Gy/fraction to subclinical disease, and 48 Gy at 1.6 Gy/fraction to elective neck. Seventeen patients received weekly cisplatin during the course of radiation therapy as well. RESULTS: With a median follow-up of 29 months for survivors (range, 14-39), the 3-year local progression-free, regional progression-free, and distant metastasis-free survival rates were 89.6%, 87.2%, and 80.4%, respectively. Treatment was well tolerated despite the grade 3 mucositis (16%) and/or pharyngitis (16%). With follow-up, the frequency of xerostomia decreased. At 3 months after IMRT, the proportions of Radiation Therapy Oncology Group grades 0, 1, and 2 xerostomia were 13%, 38%, and 50%, respectively. At 24 months, the corresponding figures were 36%, 46%, and 18%, respectively. CONCLUSION: IMRT with SIB technique for locoregionally advanced NPC was feasible and effective regarding locoregional control and development of xerostomia, even after neoadjuvant chemotherapy. Definition of gross tumor volume by postchemotherapy extent of disease was also feasible.
机译:背景:我们的目的是评估在局部晚期鼻咽癌(NPC)新辅助化疗后采用同步综合增强(SIB)技术进行强度调制放射治疗(IMRT)的可行性和有效性。方法:2004年4月至2006年12月,对25例IIB至IVB NPC患者进行了3个周期的新辅助化疗,然后采用SIB技术进行IMRT。新辅助化疗方案为5-氟尿嘧啶和顺铂治疗11例。多西他赛,5-氟尿嘧啶和顺铂为8; IMRT的剂量处方如下:IMRT的剂量为67.5 Gy(2.25 Gy /次至亚临床疾病的总分),54%至60 Gy(1.8至2 Gy /次至亚临床疾病)和1.6 Gy /次的48 Gy。选修脖子。在放射治疗期间,每周也有17名患者接受顺铂治疗。结果:幸存者的中位随访时间为29个月(范围为14-39),三年局部无进展,无区域进展和无远处转移的生存率分别为89.6%,87.2%和分别为80.4%。尽管有3级粘膜炎(16%)和/或咽炎(16%),但治疗耐受性良好。随着随访,口干的频率降低。 IMRT后3个月,放射治疗肿瘤学组的0、1、2级口腔干燥症比例分别为13%,38%和50%。在24个月时,相应的数字分别为36%,46%和18%。结论:IMRT结合SIB技术治疗局部晚期NPC即使在新辅助化疗后,对于局部控制和干燥性口干的发展也是可行和有效的。通过疾病的化疗后程度定义总肿瘤体积也是可行的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号